Latest news
IMPACT licenses ovarian cancer drug senaparib to Pharmanovia - The Pharma LetterThe Pharma Letter · Mon, 03 Aug 2026 09:00:51 GMTPharmanovia to pay IMPACT over €420M for certain rights to oral PARP1/2 inhibitor senaparib - FirstWord PharmaFirstWord Pharma · Fri, 31 Jul 2026 15:36:36 GMTPharmanovia licenses China-approved PARP drug for up to €423.5M - European Biotechnology MagazineEuropean Biotechnology Magazine · Fri, 31 Jul 2026 13:54:45 GMTIMPACT Therapeutics, Inc and Pharmanovia Enter Exclusive License Agreement For Senaparib In Europe, Middle East And North Africa, Australia And New Zealand - marketscreener.commarketscreener.com · Fri, 31 Jul 2026 10:50:46 GMTIMPACT Therapeutics Signs Exclusive License Agreement with Pharmanovia for Senaparib in Europe, Middle East and North Africa, Australia and New Zealand - The Manila TimesThe Manila Times · Fri, 31 Jul 2026 08:06:11 GMTEupraxia Pharma Partners with Pharmanovia to License Senaparib in 66 Countries Including EU; Shares Surge Over 12% - finance.biggo.comfinance.biggo.com · Thu, 30 Jul 2026 07:00:00 GMT